Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Follow-Up Questions
Who is the CEO of Biophytis SA?
Mr. Stanislas Veillet is the Chairman of the Board of Biophytis SA, joining the firm since 2015.
What is the price performance of BPTSY stock?
The current price of BPTSY is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Biophytis SA?
Biophytis SA belongs to Biotechnology industry and the sector is Health Care
What is Biophytis SA market cap?
Biophytis SA's current market cap is $0
Is Biophytis SA a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Biophytis SA, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
